A General Overview

Corneal cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system for the treatment of progressive keratoconus.

Corneal Cross-Linking:
  • Creates new corneal collagen cross-links
  • Results in a shortening and thickening of the collagen fibrils
  • Leads to the stiffening of the cornea

Top Questions to Ask Your Eye Doctor Download PDF

FDA Approval

The first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus.

In April 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.

The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.

Cross-Linking

Learn more about this outpatient procedure

View our Living with Keratoconus Patient Brochure.

Patient FAQs

Discover answers to the most common questions surrounding cross-linking

Visit the Patient FAQ Section to learn more.

It is estimated that...

1 Out of Every 2,000

persons in the general population have Keratoconus1

You can find more information from the National Keratoconus Foundation.

1. Kennedy R. H., Bourne W. M., Dyer J. A. A 48-year clinical and epidemiologic study of keratoconus. The American Journal of Ophthalmology. 1986;101(3):267–273. doi: 10.1016/0002-9394(86)90817-2.

Corneal cross-linking provides patients a much-needed option to treat this debilitating disease. Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved."

Mary Prudden, Executive Director for the National Keratoconus Foundation

What are Patients Saying? View Stories

Learn More Through Our Facebook Page

Living with KC added a new photo. ... See MoreSee Less

View on Facebook

If #KC #patients are sensitive to sunlight, what 👓 should they wear? Dr. Peter Hersh The Cornea and Laser Eye Institute, PA has the answer: ow.ly/k8TR30h1Ot1 #KCExpert ... See MoreSee Less

View on Facebook

Thomas realized his #keratoconus made playing ⚾ more challenging. See how he overcame those challenges by reading more of his story here! ow.ly/ySGQ30h24Xv ... See MoreSee Less

View on Facebook

Living with KC added a new photo. ... See MoreSee Less

View on Facebook

Want more #KC updates? Our new Q&A featuring #KCExperts answers typical questions about #LivingWithKC ow.ly/WwtT30h1Nq8 ... See MoreSee Less

View on Facebook

Learn More Through Our Twitter Page

Don't miss St. Louis Cardinals outfielder, Tommy Pham's, candid interview: https://t.co/uIrCZyN8LG where he discusses #LivingWithKC. To see more prescribing info please use link: https://t.co/G1UegjD4I6

If #KC #patients are sensitive to sunlight, what 👓should they wear? @hershvision has the answer: https://t.co/UakCoy4NC9 #KCExpert

Thomas realized his #keratoconus made playing ⚾ more challenging. See how he overcame those challenges by reading more of his story here! https://t.co/PrhVuoExtC

Want more #KC updates? Our new Q&A featuring #KCExperts answers typical questions about #LivingWithKC https://t.co/ME11zJIApX

Thomas relied on his #vision to participate in sports, but testing revealed irregularities in his #corneas. Soon after, he learned he was #LivingWithKC https://t.co/bIwOaz47M3

Load More...

Learn More Through Our Instagram

MA-00687A